Sign up to see all 5.
Sign up to see all 5.
A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.
| Holder | Shares | % of company | Change vs last qtr | 8 quarters | Held since | % of their book |
|---|---|---|---|---|---|---|
|
LC
Lynx1 Capital Management LP
13D · 21.0%
|
673.8K | 20.94% | +50.1K (+8.0%) | 2022 | 0.4% | |
|
Shares held by quarter
Peak holding9.3M (Q4'24)
Change over 8 quarters−7.8M
Share of the company20.940%
Disclosed stake13D · 21.0%
|
||||||
|
VP
Vestal Point Capital, LP
|
— | — | SOLD OUT | — | 0.0% | |
|
Shares held by quarter
|
||||||
28 more super investors behind a free account
See every manager holding Passage Bio Inc, how their position has changed, and how long they've held it.
Sign up free| Fund | Position value | Shares | % of company | % of the fund | As of |
|---|---|---|---|---|---|
|
VT
Vanguard Index Funds
|
$384K | 78.8K | 2.45% | 0.00% | June 30, 2026 |
|
VE
Vanguard Index Funds
|
$172K | 35.2K | 1.09% | 0.00% | June 30, 2026 |
12 more funds behind a free account
See every fund holding Passage Bio Inc and how much of the fund the position is.
Sign up free| Holder | Shares | % of company | Change vs last qtr | 8 quarters | Held since | % of their book |
|---|---|---|---|---|---|---|
|
WN
Weston Nichols
5%+ holder
13D · 21.0%
|
673.8K | 20.94% | — | — |
— | — |
|
This holder reports through Schedule 13D/G, not a quarterly 13F.
|
||||||
|
OA
Orbimed Advisors LLC
5%+ holder
13D · 4.3%
|
132.5K | 4.12% | — | — |
— | — |
|
This holder reports through Schedule 13D/G, not a quarterly 13F.
|
||||||
3 more holders behind a free account
See every insider and 5%+ holder of Passage Bio Inc.
Sign up freeLoading...